209 related articles for article (PubMed ID: 22064373)
1. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation.
Ząbczyk M; Majewski J; Lelakowski J
Pol Arch Med Wewn; 2011 Nov; 121(11):400-7. PubMed ID: 22064373
[TBL] [Abstract][Full Text] [Related]
2. Denser plasma clot formation and impaired fibrinolysis in paroxysmal and persistent atrial fibrillation while on sinus rhythm: association with thrombin generation, endothelial injury and platelet activation.
Drabik L; Wołkow P; Undas A
Thromb Res; 2015 Aug; 136(2):408-14. PubMed ID: 26048399
[TBL] [Abstract][Full Text] [Related]
3. Elevated NT-proBNP is associated with unfavorably altered plasma fibrin clot properties in atrial fibrillation.
Matusik PT; Matusik PS; Kornacewicz-Jach Z; Małecka B; Ząbek A; Undas A
Int J Cardiol; 2017 Sep; 243():244-250. PubMed ID: 28571619
[TBL] [Abstract][Full Text] [Related]
4. A history of early stent thrombosis is associated with prolonged clot lysis time.
Pankiw-Bembenek O; Zalewski J; Goralczyk T; Undas A
Thromb Haemost; 2012 Mar; 107(3):513-20. PubMed ID: 22274545
[TBL] [Abstract][Full Text] [Related]
5. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
6. Clot Lysis Time Predicts Stroke During Anticoagulant Therapy in Patients with Atrial Fibrillation.
Drabik L; Konieczyńska M; Undas A
Can J Cardiol; 2020 Jan; 36(1):119-126. PubMed ID: 31740169
[TBL] [Abstract][Full Text] [Related]
7. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
8. Impaired fibrinolysis in degenerative mitral and aortic valve stenosis.
Mazur P; Myć J; Natorska J; Plens K; Plicner D; Grudzień G; Kapelak B; Undas A
J Thromb Thrombolysis; 2018 Aug; 46(2):193-202. PubMed ID: 29855781
[TBL] [Abstract][Full Text] [Related]
9. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
10. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
[TBL] [Abstract][Full Text] [Related]
12. Fibrin clot properties in women heterozygous for factor V Leiden mutation: effects of oral contraceptives.
Krzek M; Ciesla-Dul M; Zabczyk M; Undas A
Thromb Res; 2012 Oct; 130(4):e216-21. PubMed ID: 22940058
[TBL] [Abstract][Full Text] [Related]
13. Lysability of fibrin clots is a potential new determinant of stroke risk in atrial fibrillation.
Skov J; Sidelmann JJ; Bladbjerg EM; Jespersen J; Gram J
Thromb Res; 2014 Sep; 134(3):717-22. PubMed ID: 25042725
[TBL] [Abstract][Full Text] [Related]
14. Vitamin K antagonists favourably modulate fibrin clot properties in patients with atrial fibrillation as early as after 3days of treatment: Relation to coagulation factors and thrombin generation.
Ząbczyk M; Majewski J; Karkowski G; Malinowski KP; Undas A
Thromb Res; 2015 Oct; 136(4):832-8. PubMed ID: 26319777
[TBL] [Abstract][Full Text] [Related]
15. Elevated 8-isoprostane concentration is associated with thromboembolic events in patients with atrial fibrillation.
Mołek P; Chmiel J; Ząbczyk M; Malinowski KP; Natorska J; Undas A
Int J Cardiol; 2022 Oct; 365():1-7. PubMed ID: 35868355
[TBL] [Abstract][Full Text] [Related]
16. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
17. Plasma Protein Oxidation as a Determinant of Impaired Fibrinolysis in Type 2 Diabetes.
Bryk AH; Konieczynska M; Rostoff P; Broniatowska E; Hohendorff J; Malecki MT; Undas A
Thromb Haemost; 2019 Feb; 119(2):213-222. PubMed ID: 30605917
[TBL] [Abstract][Full Text] [Related]
18. Induction therapy alters plasma fibrin clot properties in multiple myeloma patients: association with thromboembolic complications.
Undas A; Zubkiewicz-Usnarska L; Helbig G; Woszczyk D; Kozińska J; Dmoszyńska A; Dębski J; Podolak-Dawidziak M; Kuliczkowski K
Blood Coagul Fibrinolysis; 2015 Sep; 26(6):621-7. PubMed ID: 26083985
[TBL] [Abstract][Full Text] [Related]
19. Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction.
Cruden NL; Graham C; Harding SA; Ludlam CA; Fox KA; Newby DE
Thromb Res; 2006; 118(2):189-97. PubMed ID: 16055173
[TBL] [Abstract][Full Text] [Related]
20. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
